Osteopontin/OPN Antibody (2139B) [Alexa Fluor® 405]

• Reactivity: Mu
• Applications: WB, IHC, ICC/IF
• Clone: 2139B
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 405

Osteopontin/OPN Antibody (2139B) [Alexa Fluor® 405] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse Osteopontin/OPN
  Leu17-Asn294
  Accession # Q547B5
• Specificity: Detects mouse Osteopontin /OPN in direct ELISAs.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Osteopontin/OPN Antibody (2139B) [Alexa Fluor® 405]

• BNSP
• Bone sialoprotein 1
• Eta-1
• MGC110940
• Nephropontin
• OPN
• Osteopontin
• secreted phosphoprotein 1bone sialoprotein I, early T-lymphocyteactivation 1)
• secreted phosphoprotein-1 (osteopontin, bone sialoprotein)
• Spp1
• SPP-1
• SPP1/CALPHA1 fusion
• Urinary stone protein
• uropontin

Background

Osteopontin (OPN), previously called SPP1 (secreted phosphoprotein 1), Eta-1 (early T lymphocyte activation 1) or BSP (bone sialoprotein), is a secreted molecule in the SIBLING (small integrin-binding ligand N-linked glycoprotein) family of non-collagenous matricellular proteins (1-3). Mouse OPN is synthesized as a 294 amino acid (aa) precursor protein with a 16 aa signal peptide and a 278 aa mature protein (3). Mature mouse OPN shares 79% and 64% aa sequence identity with rat and human OPN, respectively. OPN is highly acidic and has 26 potential Ser/Thr phosphorylation sites and a C‑terminal CD44 binding site (1-4). Depending on tissue-specific modification by O- and N-glycosylation, sulfation, phosphorylation and transglutamination, OPN can be detected at 45-75 kDa (5, 6). The central region of OPN contains RGD and non-RGD binding sites for multiple integrins (3, 4). Adjacent to the RGD motif is the sequence SLAYGLR (SVVYGLR in human) which serves as a cryptic binding site for additional integrins: it is masked in full length OPN but is exposed following OPN cleavage by thrombin in tumors and sites of tissue injury
(6-8). OPN can also be cleaved by MMP-3, -7, -9, and -12 within the SLAYGLR motif and at sites closer to the C-terminus (8, 9). OPN is widely expressed and is prominent in mineralized tissues. It inhibits bone mineralization and kidney stone formation, and promotes inflammation and cell ad­hesion and migration (1, 2, 4, 6). Its expression is up-regulat­ed during inflammation, obesity, atherosclerosis, cancer, and tissue damage, and contributes to the pathophysiology of these conditions (1, 2, 6, 9, 10).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.